TW201124403A - Compounds for the treatment of hepatitis C - Google Patents

Compounds for the treatment of hepatitis C Download PDF

Info

Publication number
TW201124403A
TW201124403A TW100113021A TW100113021A TW201124403A TW 201124403 A TW201124403 A TW 201124403A TW 100113021 A TW100113021 A TW 100113021A TW 100113021 A TW100113021 A TW 100113021A TW 201124403 A TW201124403 A TW 201124403A
Authority
TW
Taiwan
Prior art keywords
solvent
minutes
column
doc
mmol
Prior art date
Application number
TW100113021A
Other languages
English (en)
Chinese (zh)
Inventor
Kap-Sun Yeung
Kyle E Parcella
John A Bender
Brett R Beno
Katharine A Grant-Young
Ying Han
Piyasena Hewawasam
John F Kadow
Andrew Nickel
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201124403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW201124403A publication Critical patent/TW201124403A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
TW100113021A 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C TW201124403A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9600508P 2008-09-11 2008-09-11

Publications (1)

Publication Number Publication Date
TW201124403A true TW201124403A (en) 2011-07-16

Family

ID=41226922

Family Applications (2)

Application Number Title Priority Date Filing Date
TW100113021A TW201124403A (en) 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C
TW098130829A TW201014836A (en) 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW098130829A TW201014836A (en) 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C

Country Status (19)

Country Link
US (1) US8048887B2 (enExample)
EP (1) EP2326633B1 (enExample)
JP (1) JP5685191B2 (enExample)
KR (1) KR20110059875A (enExample)
CN (1) CN102209717B (enExample)
AR (1) AR073740A1 (enExample)
AU (1) AU2009291966B2 (enExample)
BR (1) BRPI0918174A2 (enExample)
CA (1) CA2736988A1 (enExample)
CL (2) CL2011000527A1 (enExample)
CO (1) CO6382110A2 (enExample)
EA (1) EA019185B1 (enExample)
IL (1) IL211509A0 (enExample)
MX (1) MX2011002410A (enExample)
NZ (1) NZ591172A (enExample)
PE (1) PE20110806A1 (enExample)
TW (2) TW201124403A (enExample)
WO (1) WO2010030592A1 (enExample)
ZA (2) ZA201101739B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8399494B2 (en) * 2008-10-30 2013-03-19 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
CN102574778B (zh) * 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
BR112012006572A2 (pt) 2009-09-25 2016-04-26 Oryzon Genomics Sa inibidores de demetilase-1 de lisina específicos e seu uso
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR080433A1 (es) * 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
US8354410B2 (en) * 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
JP2013522192A (ja) * 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための化合物
AU2011244325B2 (en) 2010-04-19 2015-12-17 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US8445497B2 (en) * 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2806008C (en) 2010-07-29 2019-07-09 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CN103269586B (zh) 2010-10-26 2015-07-15 普雷西迪奥制药公司 丙型肝炎病毒抑制剂
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US8507683B2 (en) * 2010-12-09 2013-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5918264B2 (ja) * 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2013033900A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
KR102079406B1 (ko) 2011-10-20 2020-02-19 오리존 지노믹스 에스.에이. Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2831066B1 (en) 2012-03-27 2016-10-05 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2943496B1 (en) * 2013-01-10 2017-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US8962651B2 (en) 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2970174B1 (en) 2013-03-14 2017-05-03 Bristol-Myers Squibb Company Fused furans for the treatment of hepatitis c
WO2014205593A1 (en) * 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2015088958A1 (en) * 2013-12-13 2015-06-18 Bristol-Myers Squibb Company A novel compound for the treatment of hepatitis c
KR20160126085A (ko) * 2014-03-21 2016-11-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염의 치료를 위한 시아노 함유 아자벤조푸란 화합물
WO2015143256A1 (en) * 2014-03-21 2015-09-24 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US10125137B2 (en) 2015-02-19 2018-11-13 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors
US10087167B2 (en) 2015-02-19 2018-10-02 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as HCV inhibitors
US10570108B2 (en) 2015-02-19 2020-02-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis C
US10131645B2 (en) 2015-02-19 2018-11-20 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as HCV inhibitors
WO2016137832A1 (en) * 2015-02-23 2016-09-01 Bristol-Myers Squibb Company Novel compounds for the treatment of hepatitis c
WO2017165233A1 (en) * 2016-03-21 2017-09-28 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN114174283B (zh) * 2019-07-18 2023-05-12 石药集团中奇制药技术（石家庄）有限公司 作为nmt抑制剂的化合物及其应用
US20250214977A1 (en) * 2024-01-03 2025-07-03 Kymera Therapeutics, Inc. Stat6 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1372642A1 (en) 2001-03-30 2004-01-02 SmithKline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
TW200815384A (en) * 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
CA2676906A1 (en) * 2007-02-12 2008-08-21 Intermune, Inc. Novel inhibitors hepatitis c virus replication
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
EP2245023B1 (en) 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus

Also Published As

Publication number Publication date
US20100093694A1 (en) 2010-04-15
JP2012502101A (ja) 2012-01-26
CN102209717A (zh) 2011-10-05
AU2009291966A1 (en) 2010-03-18
AR073740A1 (es) 2010-12-01
ZA201101739B (en) 2012-08-29
AU2009291966B2 (en) 2014-08-28
ZA201105720B (en) 2012-08-29
CN102209717B (zh) 2015-02-18
EP2326633A1 (en) 2011-06-01
US8048887B2 (en) 2011-11-01
TW201014836A (en) 2010-04-16
WO2010030592A1 (en) 2010-03-18
IL211509A0 (en) 2011-07-31
CL2011001224A1 (es) 2011-09-16
CO6382110A2 (es) 2012-02-15
JP5685191B2 (ja) 2015-03-18
KR20110059875A (ko) 2011-06-07
EA201100390A1 (ru) 2011-10-31
CL2011000527A1 (es) 2011-08-12
MX2011002410A (es) 2011-04-05
PE20110806A1 (es) 2011-10-31
NZ591172A (en) 2012-12-21
BRPI0918174A2 (pt) 2019-10-01
EA019185B1 (ru) 2014-01-30
CA2736988A1 (en) 2010-03-18
EP2326633B1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
TW201124403A (en) Compounds for the treatment of hepatitis C
US8309558B2 (en) Compounds for the treatment of hepatitis C
AU2021381437B2 (en) Novel spiropyrrolidine derived antiviral agents
JP2013522192A (ja) Ｃ型肝炎の処置のための化合物
TW200831513A (en) Anti-viral compounds
TW200826938A (en) Hepatitis C virus inhibitors
IL302990A (en) Novel spiropyrrolidine derived antiviral agents
TW201206907A (en) Bicyclic acetyl-COA carboxylase inhibitors and uses thereof
US20230103494A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) Alkyne-containing antiviral agents
CA2620621A1 (en) Inhibitors of serine proteases
TW200938192A (en) Hepatitis C virus inhibitors
BR112020003116A2 (pt) inibidores de ahr e usos dos mesmos
WO2013007106A1 (zh) 作为丙型肝炎病毒抑制剂的螺环化合物
TW201138786A (en) Therapeutic compounds
WO2023107417A1 (en) Heterocyclic antiviral agents
JP5826856B2 (ja) ウイルスポリメラーゼ阻害剤
EP4563146A1 (en) Flavivirus inhibitors
TW201247656A (en) 2,3,5-trisubstituted thiophene compounds and uses thereof